By T.J. Coles
This is the ninth part in our series. For parts 1 to 8, see here.
Research proposals suggest that the sedative/anaesthetic, ketamine, might prevent COVID-19 from leading to serious lower respiratory infections.
The latest batch of Pfizer Papers reveals that, after testing the vaccine candidates on rats, the company hired labs to test monkeys, which tragically for animals is standard practice.
But prior to injecting the monkeys with the vaccine candidate, the unfortunate creatures were anaesthetised with ketamine: the very drug that may reduce the risk of serious infection.
So, which actually stopped the majority of monkeys from getting sick with COVID-19, the vaccine candidate or the ketamine injection?
If the latter, it means that Pfizer used faulty logic in its animal trials and then claimed that the results were effective enough to move to human experiments.
In our previous Pfizer Papers articles, we document how standard clinical practice in human trials was thrown out: studies were unblinded, a 4:1 instead of 1:1 or 2:1 vaccine candidate/placebo ratio was employed, and clinical trial phases were mixed up with so-called “stages,” with phase 4 dropped entirely.
During the pandemic and before the rollout of the injectable product, some conscientious doctors were trying to find non-vaccinal ways of treating patients with mild COVID infections in order to stop the disease from becoming more serious, such as ending in lower respiratory infection and thus the need for hospitalisation and ventilation.
Doctors also sought interventions for patients who had already reached the serious stages of COVID infection.
According to the medical doctor Matthew Sims of William Beaumont Hospitals in the US, two cheap, widely-available drugs were good candidates for preventing or reducing the inflammation that heightens the risk of serious infection.
The first was Naltrexone, a product ordinarily used for treating alcoholism and opiate addiction. The second was ketamine.
Cytokines are proteins that enable cell signalling and play a vital role in human immunity. Interleukin 6 (IL-6) is a type of cytokine produced in response to tissue damage and/or infection.
Dr. Sims says: “Promising data using tocilizumab, a monoclonal antibody targeting [IL-6] suggests that interrupting IL-6 is one of the potential pathways.”
Explaining the anti-inflammatory properties of ketamine, Sims goes on to note that “Ketamine is generally well tolerated and remains inexpensive and widely available on the U.S. market and available for immediate use.”
KILLING THE STUDY
Drs. Sims, Carl Lauter, and Annas Aljassem secured funding for the ketamine trial from private donors: Suzanne and Deborah Tyner, and from Applebaum Family Philanthropy.
The phase 2 trial would have involved working with 70 human participants, half of whom would have received placebos in a blinded trial, as per normal.
The experiment was named SINK COVID-19: Study of Immunomodulation using Naltrexone and Ketamine for COVID-19.
The project was endorsed by Margaret Cooney Case, President of the Beaumont Health Foundation, the host institution, who spoke of her gratitude towards the funders.
The recruitment statement was made in April 2020. Then, mysteriously, the project was terminated.
“Given the current study design, it is not possible to gather data necessary to answer the question about whether study treatment reduces mortality.”
Did the funders and host institution really greenlight a poorly-designed proposal, or did big pharma have something to with crushing the trial?
(It should be noted that there was perhaps no need to research the synthetic drug ketamine when natural cannabinoids had been found highly effective in treating COVID, though the authors of the separate study add the obligatory “As a compliment to vaccines” disclaimer.)
SARS-CoV-2 was declared a global pandemic in March 2020.
Yet, by April, Pfizer had already administered vaccine candidate boosters to monkeys.
Convalescent serum is blood serum taken from someone who has recovered from an infection and whose blood contains antibodies. An antibody titer is a test that measures antibodies in blood.
So-called “geometric mean concentrations” are used when the data are skewed and non-linear.
This gives an average and is not specific to the subject. So, if two subjects had high levels of antibodies and one had low levels, the result will show above-average antibodies.
Pfizer claims that rhesus macaque monkeys injected with what became Comirnaty had more than 10 times the number of antibodies as convalescent human COVID patients.
So, the so-called vaccine was less effective on people than on monkeys. We can deduce this because no one has claimed that injection-immunity produces 10 times the antibodies as natural infection.
Yet, it was permitted to advance to human trials.
Pfizer says: “All vaccinations and peripheral blood draws were performed with the macaques appropriately sedated using Ketamine HCl (10 mg/kg), administered as an intramuscular (IM) injection.”
But what if the credible proposals of Sims et al. had turned out to be correct: that ketamine reduces tissue and lung inflammation in COVID patients?
This would make it difficult to determine whether the injectable product or the ketamine had prevented/reduced infection in the monkeys.
The ketamine injection might have reduced the monkeys’ inflammations and enabled their immune systems to more effectively generate antibodies when they were infected with COVID.
Now that governments have decided that the pandemic is or is on its way to becoming endemic, the mask can finally come off (pun intended).
The business press now reports that the lack of viruses is diminishing the profits of pharmaceutical monoliths.
In the absence of novel public health crises, the giants look to niche diseases to exploit for profit.
The Financial Times says: “…as the Covid emergency recedes, the US drugmaker [Pfizer] is struggling to convince Wall Street that it can manage a transition that it forecasts will slash annual revenues by almost a third to about $70bn this year.”
It goes on to note that “Pfizer expects sales of Comirnaty, the Covid vaccine it developed with German company BioNTech, and its antiviral pill Paxlovid, to fall 62 per cent to $21.5bn in 2023, compared to last year.”
Pfizer, GSK, and Moderna are separately developing a new, injectable mRNA product, supposedly designed to protect infants against the rare respiratory syncytial virus (RSV), which kills up to 300 children aged 5 and under each year in the US.
The product will be injected into pregnant mothers.
CNBC reports that the US Food and Drug Administration “is reviewing Pfizer’s RSV vaccine on an expedited basis and will make a decision on whether to clear the shot by August.”
The mRNA products have been rapidly developed and forcibly injected into captive populations under the pretext of a public health emergency, which could have been better managed with non-risky interventions, such as increasing exercise and vitamin D consumption.
Having gotten away with it under emergency use authorisations, big pharma now sees a post-COVID opportunity to fast-track new mRNA products by hyping viruses that kill comparatively few people.
Dr. T.J. Coles is the author of several books, including — The War on You.
Check out T.J’s Amazon page by clicking here.
View more TOTT content from Coles here.
For more TOTT News:
Facebook — Facebook.com/TOTTNews
YouTube — YouTube.com/TOTTNews
Instagram — Instagram.com/TOTTNews
Twitter — Twitter.com/EthanTOTT
Bitchute — Bitchute.com/TOTTNews
Gab — Gab.com/TOTTNews